0.02%/0.04%低浓度硫酸阿托品滴眼液获批 关注近视的你了解一下

Core Viewpoint - The approval of low-concentration atropine eye drops (0.02% and 0.04%) is significant for addressing the urgent public demand for myopia prevention in children, as these products are expected to enhance personalized treatment options for managing myopia progression [1][2]. Group 1: Product Approval and Features - Two new formulations of low-concentration atropine eye drops have been approved, with concentrations of 0.02% and 0.04%, expanding the options available for myopia management in children [1]. - The introduction of these new concentrations allows for a more tailored approach to treatment, addressing individual differences in children's myopia progression [2]. Group 2: Efficacy and Safety - Clinical studies indicate that the higher concentrations (0.02% and 0.04%) show improved efficacy in slowing myopia progression compared to the previously available 0.01% concentration, with good overall tolerability [2]. - The selection of atropine concentration should follow an individualized approach, particularly for children whose myopia progresses rapidly or who have a family history of high myopia [2]. Group 3: Usage Guidelines and Misconceptions - Low-concentration atropine eye drops must be used under medical supervision, with regular follow-ups to monitor the child's response to treatment [3]. - It is important to clarify that atropine is not a "cure" for myopia; it is intended to slow progression rather than reverse existing myopia, and children still need appropriate corrective lenses [3]. - Parents should not neglect proper eye care habits, as effective myopia management also relies on good visual habits, outdoor activities, and proper lighting [3].